Merck Stock’s $1.3 Billion China Problem Goes Quiet
For questions about this article or underlying research, email help@trefis.com.
Merck (MRK) stock trades at 5.3 times sales, compared with 3.2 for the S&P 500. Investors paying that premium need to know what they are buying, and that introduces a twist: Merck’s priorities have changed. During its calls from February to July 2025, management kept returning to the slump in Gardasil vaccine sales in China. On the latest call, executives no longer emphasized that problem. So what has taken its place?

What Is Merck Talking Up Instead Of China?
New drugs and late-stage trial results. On its fiscal Q3 2026 call on October 29, 2026, management highlighted the first positive Phase III results for sac TMT, a cancer drug, in endometrial cancer, and positive Phase III data for a therapeutic cancer vaccine in melanoma. It said the quarter’s revenue reflected increased contributions from new products, as well as strength in oncology and animal health, and it pointed to continued momentum for WINREVAIR, its treatment for pulmonary arterial hypertension.
The talk sounded different in 2025. On its fiscal Q4 2024 call in February 2025, management said market dynamics for Gardasil in China had remained challenging. By the fiscal Q2 2025 call in July 2025, it put the decline in Gardasil sales in China at about $1.3 billion. Gardasil still came up on the latest call.
Gardasil Still Outsells Merck’s Newest Launches
Gardasil generated $2 billion of Merck’s $18.1 billion revenue in fiscal Q3 2026, bringing in more than any of the new launches. Excluding currency effects, its sales rose 14% from a year earlier. In the U.S., higher prices and a significant CDC purchase helped Gardasil sales grow 18%.
The newer drugs are smaller but growing faster. Reflecting strong demand and a boost from channel inventory, WINREVAIR sales rose 94% to $694 million. KEYTRUDA QLEX, the under-the-skin version of Keytruda, added $830 million during the quarter.
Both launches sit beside a much larger business. The KEYTRUDA family, which includes QLEX, grew 6% to $8.6 billion and accounted for close to half of the quarter’s revenue. The products management now highlights are growing quickly, but each still sells less than Gardasil and far less than the KEYTRUDA family.
Is Merck’s New Focus Good News For Holders?
For a holder, this is a change in emphasis, not proof that the China problem has ended. The China slump no longer dominates what management says about the business, and for 2027 management expects moderate top line growth from new product launches and animal health. That growth is partly offset by more than $2 billion of headwinds from generic competition hitting BRIDION, the Januvia family and Adempas.
Gardasil’s jump is less clean. Management said the third quarter gained $300 million from the timing of vaccine purchases, mostly Gardasil, and it expects $250 million of that to unwind in 2027. A 14% rise to $2 billion is a gain of about $0.25 billion, so this timing benefit could account for most or all of Gardasil’s growth in the quarter. It also said it is watching broader vaccine trends given increased hesitancy and reduced utilization.
Merck is expected to report its fiscal Q4 2026 results in February 2027, and Gardasil sales in that report are the measure to watch.
When the story behind one stock can change this much, having a lot riding on it is a risk worth planning around before the next change comes.
Too Much Riding On One Stock?
If Merck is a big part of your wealth, so are its risk and its tax bill. What’s your exit plan? Our partner advisory firm offers a free 30-minute strategy review covering a floor under losses and a lower-tax way out.
Spot an error or want more like this? Tell us in 10 seconds.